688065 凯赛生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.1023.8404.3143.3155.123
总资产报酬率 ROA (%)1.5372.6142.5832.0003.253
投入资产回报率 ROIC (%)2.0293.5413.7012.9234.705

边际利润分析
销售毛利率 (%)35.73334.21531.24728.79435.241
营业利润率 (%)21.09619.23318.64721.48829.015
息税前利润/营业总收入 (%)23.12716.12412.98211.23116.422
净利润/营业总收入 (%)19.45416.07016.04519.32425.097

收益指标分析
经营活动净收益/利润总额(%)91.655114.244108.87384.925101.863
价值变动净收益/利润总额(%)-2.0120.222-1.633-1.742-0.533
营业外收支净额/利润总额(%)6.119-0.569-0.647-1.196-1.766

偿债能力分析
流动比率 (X)5.2495.8472.5322.2205.951
速动比率 (X)4.6315.1292.1271.7904.846
资产负债率 (%)12.28710.75020.61021.55915.645
带息债务/全部投入资本 (%)2.0230.88611.48710.8726.125
股东权益/带息债务 (%)4,746.13010,950.852745.335791.0821,478.054
股东权益/负债合计 (%)587.302689.393293.516274.962392.567
利息保障倍数 (X)35.264-5.374-2.341-1.123-1.358

营运能力分析
应收账款周转天数 (天)34.03529.75629.84753.94947.911
存货周转天数 (天)209.797217.617234.276363.485314.122